Clinical Trials Logo

Organ Transplant Recipients clinical trials

View clinical trials related to Organ Transplant Recipients.

Filter by:
  • None
  • Page 1

NCT ID: NCT04642287 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

NCT ID: NCT04329221 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 1, 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-fluorouracil cream as an immunotherapy for actinic keratosis in Organ Transplant Recipients (OTRs) before transplantation and determine whether it can prevent cutaneous squamous cell carcinoma (SCC) in OTRs post-transplant.

NCT ID: NCT03438058 Completed - Clinical trials for Organ Transplant Recipients

Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation

Start date: January 2017
Phase: N/A
Study type: Observational

This project will involve a systematic literature review and meta-analysis of studies assessing the impact of complement-activating anti-Human Leukocyte Antigen (HLA) donor specific antibodies (DSA) on the allograft survival rate and on the rejection rate. This meta-analysis will assess the role of complement activating anti-HLA DSAs across the entire transplant field including kidney, liver, lung and heart transplant recipient's studies.

NCT ID: NCT00829192 Active, not recruiting - Clinical trials for Carcinoma, Squamous Cell

Phase II AK Study in Organ Transplant Patients

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are at particularly high risk, over a 24 month test period. The number of lesions formed on the head, hands and forarms will be monitored over this 24 month test period.